These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 12891312)

  • 21. Approach to antiarrhythmic therapy in patients with ICDs and frequent activations.
    Pinter A; Dorian P
    Curr Cardiol Rep; 2005 Sep; 7(5):376-81. PubMed ID: 16105494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Unmotivated malfunction of implanted cardioverter-defibrillator and ways of its correction].
    Tiroke A; Ganeeva ON; Syrkin AL
    Klin Med (Mosk); 2003; 81(5):26-30. PubMed ID: 12856564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.
    Pacifico A; Hohnloser SH; Williams JH; Tao B; Saksena S; Henry PD; Prystowsky EN
    N Engl J Med; 1999 Jun; 340(24):1855-62. PubMed ID: 10369848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry.
    Marcus GM; Glidden DV; Polonsky B; Zareba W; Smith LM; Cannom DS; Estes NA; Marcus F; Scheinman MM;
    J Am Coll Cardiol; 2009 Aug; 54(7):609-15. PubMed ID: 19660690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Management of arrhythmias in patients with heart failure].
    Le Heuzey JY; Copie X; Piot O; Lavergne T; Henry P; Guize L
    Arch Mal Coeur Vaiss; 1998 Nov; 91(11):1371-6. PubMed ID: 9864606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias.
    Satomi K; Kurita T; Takatsuki S; Yokoyama Y; Chinushi M; Tsuboi N; Nitta T; Shoda M; Mitamura H
    Circ J; 2006 Aug; 70(8):977-84. PubMed ID: 16864928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a role for amiodarone in the era of the implantable cardioverter-defibrillator?
    Eckardt L; Breithardt G
    Heart Rhythm; 2006 Apr; 3(4):484-7. PubMed ID: 16567301
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification and management of ventricular tachycardia.
    Naik N; Talwar KK
    J Indian Med Assoc; 2003 Feb; 101(2):62-5, 95. PubMed ID: 12841484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators.
    Dougherty AH
    Curr Opin Cardiol; 1996 Jan; 11(1):2-8. PubMed ID: 8664528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs for ventricular arrhythmias in the era of the implantable cardioverter defibrillator.
    Peters NS
    Eur Heart J; 1999 Mar; 20(5):321-3. PubMed ID: 10206376
    [No Abstract]   [Full Text] [Related]  

  • 34. Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
    Ferrari R; Cinca J; Marber M
    Eur Heart J; 1999 Mar; 20(6):397-8. PubMed ID: 10213339
    [No Abstract]   [Full Text] [Related]  

  • 35. [Role of electrophysiology in the prognosis and therapy of cardiomyopathies].
    Laurenzi F; Avella A; Adinolfi E; Dini P
    G Ital Cardiol; 1999 Oct; 29(10):1190-4. PubMed ID: 10546132
    [No Abstract]   [Full Text] [Related]  

  • 36. A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias.
    Garan H
    Prog Cardiovasc Dis; 1996; 38(6):455-6. PubMed ID: 8638026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator patients: Insights from the German DEVICE registry.
    Wiedmann F; Ince H; Stellbrink C; Kleemann T; Eckardt L; Brachmann J; Gonska BD; Kääb S; Perings CA; Jung W; Lugenbiel P; Hochadel M; Senges J; Frey N; Schmidt C
    Heart Rhythm; 2023 Apr; 20(4):501-509. PubMed ID: 36509321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac surgery: postoperative arrhythmias.
    Chung MK
    Crit Care Med; 2000 Oct; 28(10 Suppl):N136-44. PubMed ID: 11055682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of ventricular arrhythmias.
    Aronow WS
    Compr Ther; 2008; 34(2):89-99. PubMed ID: 18833785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The implantable defibrillator and antiarrhythmic drugs--competitive and complementary treatment for severe ventricular arrhythmia.
    Dorian P; Newman D
    Clin Cardiol; 1993 Nov; 16(11):827-30. PubMed ID: 8269662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.